Artificial-intelligence-driven rational design of nanoparticle-mediated targeted protein degradation

Targeted protein degradation (TPD) has emerged as a powerful therapeutic strategy to eliminate disease-associated proteins that are inaccessible to conventional inhibition.Among TPD approaches, nanoparticle-mediated degradation, particularly through nanoparticle-mediated targeting chimerics (NPTACs) that induce receptor-mediated endocytosis and lysosomal degradation, offers unique advantages in modular design, target selectivity, and delivery potential.However, the complexity of these systems, determined by factors including particle size, surface charge, PEGylation, and ligand properties, poses significant challenges in predicting which formulations will effectively mediate intracellular trafficking and protein degradation.This perspective proposes artificial intelligence (AI) as a transformative tool to enable rational, predictive, and personalized NPTAC design.By integrating curated datasets, machine learning, generative modeling, and mechanistic insights, AI can navigate vast design spaces and accelerate translation.We outline key opportunities, challenges, and a future vision for intelligent, patient-tailored degrader nanomedicines.

Authors

Institutions

Publication Details

Journal
Cell Biomaterials
Published
2026-04-01
DOI
https://doi.org/10.1016/j.celbio.2026.100443
Primary Topic
Peptidase Inhibition and Analysis
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Artificial-intelligence-driven rational design of nanoparticle-mediated targeted protein degradation

Bingyang Shi, Yang Liu, Xue Xia, Wei Deng et al.
Cell Biomaterials
Peptidase Inhibition and Analysis
article

Artificial-intelligence-driven rational design of nanoparticle-mediated targeted protein degradation

Bingyang Shi, Yang Liu, Xue Xia, Wei Deng, David Gallego Ortega, Runhan Liu
article en

Abstract

Targeted protein degradation (TPD) has emerged as a powerful therapeutic strategy to eliminate disease-associated proteins that are inaccessible to conventional inhibition.Among TPD approaches, nanoparticle-mediated degradation, particularly through nanoparticle-mediated targeting chimerics (NPTACs) that induce receptor-mediated endocytosis and lysosomal degradation, offers unique advantages in modular design, target selectivity, and delivery potential.However, the complexity of these systems, determined by factors including particle size, surface charge, PEGylation, and ligand properties, poses significant challenges in predicting which formulations will effectively mediate intracellular trafficking and protein degradation.This perspective proposes artificial intelligence (AI) as a transformative tool to enable rational, predictive, and personalized NPTAC design.By integrating curated datasets, machine learning, generative modeling, and mechanistic insights, AI can navigate vast design spaces and accelerate translation.We outline key opportunities, challenges, and a future vision for intelligent, patient-tailored degrader nanomedicines.

Cell Biomaterials
University of Technology Sydney (AU)
Australian Research Council, National Health and Medical Research Council
Zero hunger
Openalex Percentile: Top 21%
Peptidase Inhibition and Analysis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.